StockDuty ← Dashboard Oct 27, 2026 03:53 PM ET
SignalCorporate

Kiniksa targets $1.045B-$1.050B 2026 revenue as KPL-387 data expected in H2 2027

Kiniksa issued 2026 revenue guidance and set KPL-387 data timing for H2 2027.

Context
What happened: Kiniksa Pharmaceuticals raised its full year revenue guidance and said KPL-387 data is expected in H2 2027, per the Q3 2026 earnings call. Key numbers: Full year revenue guidance raised to $1.045 billion to $1.050 billion. KPL-387 data expected in H2 2027. Why it matters: The CEO said the company continues to see robust performance, and the raised guidance reflects an improved full year revenue outlook.
What changed
Kiniksa Pharmaceuticals raised its full year revenue guidance and said KPL-387 data is expected in H2 2027, per the Q3 2026 earnings call.
Why it matters
The CEO said the company continues to see robust performance, and the raised guidance reflects an improved full year revenue outlook.
Sources
seekingalpha
Related signals
FITCH AFFIRMS CHINA CREDIT RATING AT 'A' →FITCH ISSUES NEW STATEMENT AND OUTLOOK ON U.S . CREDIT RATING DEBT WARNING IN FIRST PARAGRAPH . →$FMX →